Retatrutide
Retatrutide dosing, mechanism of action, side effects, and clinical evidence. Complete reference for healthcare professionals.
Weight LossSubcutaneous injection1-12mg weekly (investigational)
Overview
Retatrutide is a triple agonist of GIP, GLP-1, and glucagon receptors, currently in Phase 3 trials showing up to 24% weight loss.
Mechanism of Action
- Triple receptor agonism — GIP + GLP-1 + glucagon receptors
- Superior weight loss — Up to 24% body weight reduction in trials
- Metabolic improvement — Significant HbA1c and lipid improvements
- Glucagon component — May enhance energy expenditure
Dosing (Investigational)
Phase 2 trials used 1-12mg weekly. Phase 3 ongoing.
Status
Not yet approved. Eli Lilly Phase 3 trials (TRIUMPH) ongoing. Expected FDA submission pending trial completion.
Last updated: 2026-03-27